Investigational Drug Information for Surufatinib
✉ Email this page to a colleague
What is the development status for investigational drug Surufatinib?
Surufatinib is an investigational drug.
There have been 68 clinical trials for Surufatinib.
The most recent clinical trial was a Phase 2 trial, which was initiated on December 7th 2015.
The most common disease conditions in clinical trials are Carcinoma, Neuroendocrine Tumors, and Neoplasms. The leading clinical trial sponsors are Hutchison Medipharma Limited, Sun Yat-sen University, and Fujian Cancer Hospital.
There are two US patents protecting this investigational drug and twenty-one international patents.
Summary for Surufatinib
| US Patents | 2 |
| International Patents | 21 |
| US Patent Applications | 13 |
| WIPO Patent Applications | 9 |
| Japanese Patent Applications | 1 |
| Clinical Trial Progress | Phase 2 (2015-12-07) |
| Vendors | 44 |
Recent Clinical Trials for Surufatinib
| Title | Sponsor | Phase |
|---|---|---|
| A Study of Surufatinib Combined With Serplulimab in the Treatment of Advanced Solid Tumors With Neuroendocrine Differentiation That Failed Standard Therapy | Shanghai Changzheng Hospital | N/A |
| A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors | Changhai Hospital | Phase 2 |
| A Study of Surufatinib in the Treatment of Advanced Soft Tissue Sarcoma | Fudan University | N/A |
Clinical Trial Summary for Surufatinib
Top disease conditions for Surufatinib
Top clinical trial sponsors for Surufatinib
US Patents for Surufatinib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Surufatinib | ⤷ Sign Up | Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use | Hutchison MediPharma Limited (Shanghai, CN) | ⤷ Sign Up |
| Surufatinib | ⤷ Sign Up | Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use | Hutchison Medipharma Limited (Shanghai, CN) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Surufatinib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Surufatinib | Australia | AU2010321366 | 2029-11-23 | ⤷ Sign Up |
| Surufatinib | Brazil | BR112012012138 | 2029-11-23 | ⤷ Sign Up |
| Surufatinib | Canada | CA2781066 | 2029-11-23 | ⤷ Sign Up |
| Surufatinib | China | CN102070618 | 2029-11-23 | ⤷ Sign Up |
| Surufatinib | China | CN102648194 | 2029-11-23 | ⤷ Sign Up |
| Surufatinib | Denmark | DK2504331 | 2029-11-23 | ⤷ Sign Up |
| Surufatinib | European Patent Office | EP2504331 | 2029-11-23 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
